UK markets close in 4 hours 19 minutes

Koninklijke Philips N.V. (PHG)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
20.41+0.35 (+1.74%)
At close: 04:00PM EDT
20.42 +0.01 (+0.05%)
Pre-market: 06:50AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close20.06
Open20.66
Bid20.45 x 2900
Ask20.44 x 1800
Day's range20.34 - 20.71
52-week range17.75 - 24.27
Volume1,189,207
Avg. volume1,025,362
Market cap18.584B
Beta (5Y monthly)0.78
PE ratio (TTM)N/A
EPS (TTM)-0.51
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date12 May 2022
1y target est20.56
  • Reuters

    Philips shares rise on final US deal on sleep apnea machines

    Philips said it had reached what is known as a consent decree that spells out the improvements it needs to make at its Respironics plants in the United States. In January, Philips said the costs of the consent decree led to a provision of 363 million euros in the fourth quarter of 2023, and were expected to be about 1% of total revenue in 2024. The agreement followed the recall of millions of breathing devices and ventilators used to treat sleep apnea in 2021, because of concerns that foam used to reduce noise from the devices could degrade and become toxic, carrying potential cancer risks.

  • GlobeNewswire

    Philips Respironics reaches agreement with US government on a consent decree creating a clear path forward

    April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA and Philips Respironics have now reached final agreement on the consent decree with the DOJ and FDA. As previously stated: The consent decree primarily focuses on Philips Respironics’ business operations in the US.It provides clarity and a roadmap to demonstrate compliance with regulatory requirements and to restore

  • Reuters

    US federal court orders Philips to restrict production of sleep apnea devices

    (Reuters) -A U.S. federal court issued a decree to restrict the production and sale of Philips' new sleep apnea machines at several facilities in the country, the Food and Drug Administration said on Tuesday. The U.S. District Court for the Western District of Pennsylvania has entered into what is known as a consent decree against the company's subsidiary Philips Respironics to curb the sale and production until certain requirements are met. In January, the Dutch health technology company had said that it will not sell new devices to treat sleep apnea in the United States in the coming years as it works to comply with a settlement with the FDA.